Isoniazid ELISA Kit

niazid, also known as isonicotinylhydrazide (INH), is a key drug used for the treatment of the deadly infectious disease tuberculosis (TB). TB is caused by a bacterium called Mycobacterium tuberculosis and is one of the most fatal diseases in the world. According to the Global tuberculosis report 2018, TB kills over 4,000 people each day. Currently INH is a first-line medication used to treat TB but it is often used along with other antibiotics such as rifampicin, pyrazinamide and/or ethambutol because of the raise of multidrug-resistant microorganisms. INH is a prodrug and must be first activated by the enzyme called KatG in Mycobacterium tuberculosis. Then the activated INH can interact with the cofactor NADH to form an adduct which binds tightly to the bacterial InhA enzyme to block cell wall synthesis. Some mycobacteria have evolved to mutate KatG to develop INH resistance and it has become a public health threat now. INH has some side effects such as numbness, higher liver enzymes in blood and liver inflammation and therefore it is important to monitor the INH concentrations in TB patients. The traditional techniques/instruments (HPLC or GC-MS) for detecting INH are expensive, laborious, and time-consuming. On the other hand, immunoassay techniques, such as ELISA, are commonly preferred as simple, reliable and rapid methods. BioVision’s INH ELISA kit is a competitive-based ELISA that can quickly and reliably determine a broad range of INH concentrations in human serum samples. It can detect INH (0.2 – 45 μg/ml) within 90 minutes.